Explore

Trendline Trendline
Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM

Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM

Alnylam Pharmaceuticals to Present Vutrisiran Data at Heart Failure 2026, Highlighting Efficacy in ATTR-CM
Trendline Trendline
Alnylam to Showcase Vutrisiran's Efficacy in ATTR-CM at Heart Failure 2026

Alnylam to Showcase Vutrisiran's Efficacy in ATTR-CM at Heart Failure 2026

Alnylam to Showcase Vutrisiran's Efficacy in ATTR-CM at Heart Failure 2026
Trendline Trendline
Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark

Summit Shares Plummet as PD-1/VEGF Drug Fails Early Survival Benchmark
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request

Passage Bio Announces Major Workforce Reduction Following FDA Trial Design Request
Trendline Trendline
FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data

FDA Approves Pfizer and Arvinas' Veppanu for Breast Cancer Treatment Despite Mixed Data
Trendline Trendline
FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients

FDA Reviews Argenx's Proposal to Expand Vyvgart Label for Myasthenia Gravis Patients
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement

Passage Bio to Cut 75% of Workforce Following FDA Trial Design Requirement
Trendline Trendline
Molecular Partners AG Reports Positive Phase 1 Results for MP0317, Initiates Phase 2 Trial in Cholangiocarcinoma

Molecular Partners AG Reports Positive Phase 1 Results for MP0317, Initiates Phase 2 Trial in Cholangiocarcinoma

Molecular Partners AG Reports Positive Phase 1 Results for MP0317, Initiates Phase 2 Trial in Cholangiocarcinoma
Trendline Trendline
Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement

Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement

Axsome Therapeutics' Auvelity Approved by FDA for Alzheimer's Agitation, Marking a Significant Advancement
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain